Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ACTR3P2 encodes a non-functional genomic remnant broadly homologous to the actin-related protein 3 (ACTR3), which is a part of the Arp2/3 complex that mediates actin nucleation, cell migration, and various cytoskeletal functions[1][3]. However, as a pseudogene, ACTR3P2 does not produce a functional protein and is not implicated in cellular signaling, disease, or therapeutic targeting. Pseudogenes, including ACTR3P2, generally arise from ancestral coding genes through duplication or retrotransposition; they typically do not produce functional protein products nor contribute directly to biological pathways[2][4]. There is no evidence of involvement in human disease or responsiveness to known drugs. Key notes: - ACTR3P2 should not be mistaken for ACTR3, which is a protein-coding gene and a core component of the actin cytoskeleton regulation machinery[3]. - The inclusion of “pseudogene” in its name and lack of protein product/output means this should not be considered a therapeutic target. - Any references to actin nucleation, cytoskeletal organization, or related disease associations apply only to ACTR3 and the Arp2/3 complex, not ACTR3P2[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ACTR3 actin-related protein 3 homolog pseudogene 2 (ACTR3P2).